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SUMMARY
Cancer-related fatigue is the most prevalent cancer symptom, reported in 50%-90% of 
patients and severely impacts quality of life and functional capacity. The condition re-
mains underreported and often goes untreated. Guidelines suggest screening for fatigue 
at the initial visit, when the diagnosis of advanced disease is made, and at each chemothe-
rapy session, as well as the identification of treatable contributing factors such as anemia, 
hypothyroidism, depression and sleep disorders. Brief assessment tools such as the Brief 
Fatigue Inventory or the Visual Analog Scale may be appropriate in the initial scoring 
of fatigue severity, but the initial approach to treatment usually requires a more com-
prehensive assessment, education, and the determination of an individualized treatment 
plan. Patients with moderate or severe fatigue may benefit from both pharmacological 
and non-pharmacological interventions, whereas mild fatigue that does not interfere 
with quality of life can be treated with non-pharmacological measures alone. Non-phar-
macological measures that have shown to be promising include cognitive-behavioral 
interventions such as energy conservation and activity management (ECAM), exercise 
and perhaps sleep therapy. Many other modalities may be beneficial and can be used on 
an individual basis, but there is insufficient evidence to promote any single treatment. 
Pharmacological therapies that have shown to be promising include the psycho-stimu-
lants methylphenidate and dexmethylphenidate, modafinil (in severely fatigued patients 
only), and erythropoietin-stimulating agents in patients with chemotherapy-associated 
anemia and hemoglobin levels < 10 g/dL. Recently, our group reported impressive results 
with the use of the dry extract of Guarana (Paullinia cupana), with no significant side 
effects and at low cost, for the treatment of physical and mental cancer-related fatigue. 
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INTRODUCTION
Cancer-related fatigue (CRF) is a common and treatable 
symptom that severely affects numerous aspects of the 
cancer patient’s quality of life1. Patients report fatigue as 
one of the most important and stressful symptoms related 
to cancer and its treatment2. This symptom is a strong and 
independent predictor of the decrease in patients’ perso-
nal satisfaction and quality of life3. Although the current 
recommendations suggest a customary investigation for 
CRF4, this symptom remains underreported and generally 
does not receive adequate treatment for several reasons2, 
which will be discussed in this review. 
The estimated prevalence varies widely, reflecting a di-
versity of populations in which the symptom has been stu-
died. Similarly, studies have assessed the subjective nature 
of such condition and the several methods employed in 
its diagnosis. Around 50% to 90% of cancer patients expe-
rience fatigue in general5-9, with the latter figure represen-
ting patients submitted to anti-cancer treatment such as 
chemotherapy (CT) and radiotherapy (RT)7. Fatigue can 
be a symptom that persists for months to years in this po-
pulation after CT; in one study, a third of the patients that 
had been cured from cancer still experienced fatigue five 
years after the end of treatment10 and in another study, fati-
gue was referred by 60% of patients with Hodgkin’s disease 
that had been disease-free for five years. 
According to the recommendations of the National 
Comprehensive Cancer Network (NCCN), cancer-related 
fatigue is defined as a persistent symptom, a subjective 
feeling of physical, emotional or cognitive tiredness or 
exhaustion related to cancer or its treatment that is not 
proportional to the recently performed activity, and which 
can interfere with the usual patient’s functional capacity4.  
The pathogenesis of cancer-related fatigue has not 
been thoroughly described and several mechanisms can 
contribute to its development11. Among the described 
mechanisms are the effects of cancer and its treatment on 
the central nervous system, muscle energetic metabolism, 
sleep, circadian rhythm12, inflammatory and stress media-
tors13, immune system activation14,15, hormonal alterations 
related the effects on hypothalamus-pituitary axis, early 
menopause16, or androgen-deprivation in men11-22. 
CRF is very common in patients submitted to RT23 and 
in a large number of patients receiving biological modi-
fiers, such as Interferon and Interleukin 224. Modifiable 
and reversible causes that can collaborate to the develo-
pment of fatigue, such as hypothyroidism25,26, depression 
and anemia27 must be always investigated and treated. 
DIAGNOSIS AND APPROACH OF CANCER-RELATED FATIGUE  
The NCCN currently suggests that all patients with can-
cer must be investigated for cancer-related fatigue during 
the initial consultation, when the diagnosis of advanced 
disease is attained and at each visit for CT administration. 
Although the established guidelines are clear, there are 
impediments related to the diagnosis of fatigue and the 
patients’ reports on symptoms related to their routine 
that can be significantly altered. Physicians sometimes 
have insufficient knowledge on fatigue and its treatment 
or can underestimate its impact on patient quality of life, 
whereas patients might consider fatigue symptoms as a 
an inevitable consequence of cancer treatment, among 
the several other side effects to which they are submitted 
when start treatment with certain medications. 
The patient’s major objective of attaining cure or re-
mission of the disease can corroborate the fear of repor-
ting symptoms and receiving a less aggressive treatment 
that can result in a lower chance of cure. Side and adver-
se effects become a bridge through which the expected 
clinical improvement are achieved, whereas important 
symptoms, such as fatigue, end up unreported and un-
treated6,28,29. 
Several instruments used in the investigation and ap-
proach of cancer-related fatigue management have alre-
ady been validated, but none of them is a sole diagnostic 
modality.  The diagnosis can be achieved through a com-
bination of clinical history and physical examination, 
relevant laboratory assessment, information obtained 
from family members or caregivers that are part of the 
patient’s daily life and the use of standardized measures 
to assess fatigue (Figure 1). The simplest (fastest and ea-
siest) among these measures are the Visual Analog Sca-
le (VAS) and the Brief Fatigue Inventory (BFI)4,16,30. The 
FACIT-F (The Functional Assessment of Cancer Therapy 
Instrument)31 and MFSI-SF (Multidimensional Fatigue 
Symptom Inventory-Short Form)32 questionnaires have 
been validated in several languages; however, there are 
some other questionnaires that are not so detailed and 
therefore, not so often employed in clinical research. 
The diagnosis of cancer-related fatigue is usually achie-
ved after the exclusion of reversible or treatable causes 
of fatigue, such as hypothyroidism, anemia, sleep disor-
ders, pain, emotional stress, menopause, medication ad-
verse effects, electrolytic disorders or pathologies, such 
as heart failure, myopathies and pulmonary fibrosis, for 
instance33,34. Once these potential contributing factors 
are evaluated, the patients must be investigated throu-
gh a brief and self-explanatory questionnaire such as the 
VAS or the BFI34. Patients with moderate or severe fati-
gue can benefit from an association of pharmacological 
and non-pharmacological treatments, whereas those with 
mild fatigue, which does not interfere with their quality 
of life, can receive non-pharmacological treatment only4. 
The follow-up of disease severity and impact on quality of 
life, as well as patient’s functionality must be carried out 
often. CRF evaluation and classification must be the first 
step in the clinical interpretation of cancer patients, so 
that an adequate treatment strategy can be implemented. 
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Figure 1 –  Algorithm for diagnosis and treatment of cancer-
related fatigue.
Cancer diagnosis is attained
Multidisciplinary assessment
YES
Mild (1 to 3)
Non-pharmacological treatment
Acupuncture
Pharmacological treatment
Methylphenidate: 5 mg 2x day (up to 20 mg/day)
Guarana (dry extract): 50 mg 2x day
Antidepressants if fatigue is 
accompanied  by depression
Modafinil: 100 to 200 mg in the morning
Corticoids: for patients with terminal or 
advanced cancer due to side effects
– Cognitive-behavioral therapy
– Individual counseling for stress 
and anxiety management
– Sleep therapy 
– Physical  exercises: avoid in 
patients with associated diseases 
and contraindications, such as:
metastases with osteolytic lesions 
and imminent fracture risk, for 
instance
Moderate to severe (4 or higher)
NO
Anamnesis and physical examination
– Nutritional, metabolic and hormonal 
status: anemia, hypothyroidism, menopause, 
water-electrolytic imbalance, dehydration, 
malnutrition.
– Comorbidities: cardiological assessment, 
pulmonary diseases
– Pain assessment and adequate therapy 
implementation
Treat diagnosed pathologies
Apply questionnaire: Visual Analog Scale
Screen for cancer-related fatigue before  
starting any therapy
CRF evaluation and classification should be the first 
step in the clinical assessment of cancer patients for the 
implementation of an appropriate treatment strategy. 
Reassessment regarding the patient’s treatment progress 
can be carried out through the questionnaires used for 
CRF screening and thus, a behavior pattern of the fatigue 
is established, providing differentiated treatment options 
for different patients with different types of tumors and 
distinct disease stages and treatment. Patients with mild 
fatigue can start non-pharmacological therapies and be 
reassessed during treatment. In case of persistent fatigue 
or worsening of the initial condition, combined therapy 
is indicated. The combined therapy is also indicated for 
patients diagnosed with moderate or severe fatigue at the 
diagnosis. 
NON-PHARMACOLOGICAL TREATMENT
The initial approach of CRF requires a comprehensive 
view and understanding by patients of their own symp-
toms, which normally requires the establishment of indi-
vidualized treatment. Expectations regarding treatment 
must be clear and agreed so that there are no frustrations 
or promises of improvement bigger than what the treat-
ment can offer, which will guarantee the success of the the-
rapy instituted for each patient34. 
Most patients with fatigue will benefit from a non- 
pharmacological treatment.  A review of 77 randomized 
controlled studies involving non-pharmacological treat-
ment for CRF showed benefits obtained with the following 
measures: cognitive-behavioral therapy, exercises, hypno-
sis, relaxation and psychoeducation for fatigue35. The most 
relevant and effective non-pharmacological treatments to 
date will be described next.
EXERCISES
According to the most recent recommendations, the most 
effective measure against CRF is the regular practice of 
physical exercises. However, only a minority of patients 
are advised on how to implement an exercise routine that 
is effective and adequate for daily life. Studies on physical 
exercises in patients with fatigue consistently showed their 
benefits in fighting fatigue, improving quality of life and 
functional capacity, reducing stress and improving several 
other symptoms36-50. Regular physical exercises increase 
functional capacity and thus, decrease the necessary effort 
to perform activities of daily living (ADL)51. The type of 
exercise is not as important as the simple fact of perfor-
ming a physical activity37,52. Allowing the patient the pos-
sibility of choosing the best exercise that can be adapted to 
his or her routine, and to give the information and incen-
tive to accomplish these activities turn out to be essential 
to attain excellent results50. A recent meta-analysis that as-
sessed behavioral interventions and physical exercises for 
CRF evaluated 56 studies and found statistically significant 
benefits with both interventions53.
COGNITIVE-BEHAVIORAL THERAPY 
Many patients with CRF can benefit from some type of 
psychological intervention and a number of modalities 
have been studied in several different populations. Inter-
ventions such as group therapy54,55, individual counse-
ling56, stress reduction with relaxation training57-60, formal 
cognitive-behavioral therapy61-64, education for fatigue 
management65, and support therapies66 have shown pro-
mising results. 
In a systematic review of 27 studies, the data demons-
trated that interventions focused specifically on fatigue are 
more effective than nonspecific interventions67. For ins-
tance, the Strategy of Energy Conservation and Activity 
Management (ECAM) was studied in 396 patients with 
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cancer and fatigue. The patients were randomly distribu-
ted to receive advice on diet and nutrition or ECAM, in 
addition to the monitoring of several activities and levels 
of fatigue attributed to these activities. A small benefit was 
observed in the treatment of CRF in the group treated with 
ECAM68. 
SLEEP DISORDERS
Difficulty to sleep is a frequent problem for cancer pa-
tients, which might be directly related to the pathology, 
the consequences of treatment69, or the emotional stress 
caused by the treatment. Benefits have been demonstrated 
with sleep hygiene therapy, which is simply a compilation 
of practices that try to introduce different habits before 
bedtime into the life of patients and are related to the im-
provement in functional capacity to perform ADL, sleep 
quality parameters69, and fatigue improvement in rando-
mized controlled clinical trials70. However, an important 
randomized study with 219 patients with breast cancer did 
not show any benefits regarding individualized sleep qua-
lity improvement therapy in comparison to controls when 
the CRF was assessed in these patients71. Therefore, it is 
clear that behavioral interventions improve sleep quality; 
however, the impact of these therapies on the treatment of 
CRF is yet to be clarified.  
ALTERNATIVE AND COMPLEMENTARY MEDICINE 
The possible benefits of alternative treatments for CRF 
have yet to be elucidated. Two clinical studies have sugges-
ted the benefits of acupuncture in the treatment of fatigue. 
In the first study, 37 patients with persistent fatigue were 
treated with 6 to 8 sessions of acupuncture, after which 
they demonstrated a statistically significant improvement 
at the BFI, when compared with their baseline assess-
ments. In another study, 47 patients with fatigue were ran-
domized and received acupuncture, acupressure or sham 
acupuncture. A significant benefit was found to be favo-
rable to acupuncture when compared to acupressure and 
sham acupuncture72. 
PHARMACOLOGICAL TREATMENT 
Patients with moderate to severe CRF can benefit from 
pharmacological treatments together with non-pharma-
cological treatments, especially if quality of life or the dai-
ly activities are impaired as a direct consequence of these 
symptoms73. 
METHYLPHENIDATE/DEXMETHYLPHENIDATE
Psychostimulants have shown to be a promising option 
that will be part of a multimodal therapy for the treat-
ment of CRF. Several small studies have suggested that 
methylphenidate improves fatigue74-77. Additional bene-
fits of this medication have been reported regarding the 
following symptoms: anxiety, appetite, nausea, pain and 
drowsiness74; moreover, cognitive and functional capaci-
ty improvement was observed in studies with 12 patients 
with melanoma76 and 30 patients with brain tumors78.
Randomized clinical studies have been carried out 
with this medication. A small double-blind crossover 
study suggested that methylphenidate would potentiate 
the analgesic effects of narcotics used by the patients and 
would decrease the drowsiness caused by these medica-
tions79. However, negative results were found in a rando-
mized study with 112 patients that had fatigue and can-
cer and received methylphenidate or placebo for 7 days. 
A nurse contacted the patients daily by telephone un-
til day 8 and on each day, fatigue was measured through 
the FACIF-F (primary outcome). After this period, the 
patients could choose to receive four additional weeks of 
methylphenidate. A significant benefit in the treatment of 
fatigue was observed in both groups, the one that received 
placebo and the one that received methylphenidate, with 
no difference between the groups. When compared with 
the patients that received placebo, a significant number of 
those that received methylphenidate for eight days did not 
choose to receive this medication after this period, as they 
could have chosen to do, if they had perceived symptom 
improvement during the time when they were receiving 
the medication. This study recalls the therapeutic power 
of the placebo effect and the role of non-pharmacological 
interventions, such as telephone calls made by a nurse and 
the comfort that simple and effective measures can have as 
therapeutic action against fatigue80.  
Dexmethylphenidate was assessed in a randomized 
controlled double-blind phase II study that consisted of 
assessment of 154 patients with fatigue that received at 
least four cycles of CT for treatment of breast and ova-
rian cancer, predominantly. A significant improvement 
in CRF was observed in the arm that received treatment 
when compared to the placebo group; however, the-
re were more adverse effects and medication withdra-
wal in the group that received dexmethylphenidate81. A 
meta-analysis evaluating both studies mentioned above, 
however, concluded that methylphenidate or dexme-
thylphenidate was more effective than placebo for the 
treatment of CRF82. 
Modafinil: Benefits have been observed regarding 
the action of modafinil on the central nervous system of 
patients with CRF in a randomized, placebo-controlled 
study with 642 patients published as an abstract. Patients 
reported fatigue through a scale that scored the level of 
fatigue between 1 and 10. Although there was a signifi-
cant difference between the two study arms in favor of 
modafinil, the improvement was much more significant 
in patients that had severe fatigue at baseline83. Two non-
randomized pilot studies suggested a possible benefit of 
modafinil in the treatment of CRF84,85.
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ERYTHROPOIETIN-STIMULATING AGENTS
Many patients with cancer develop anemia as a consequen-
ce of the malignity, treatment or even the comorbidities 
that they previously presented. Anemia is one of the main 
reversible causes of CRF27. When the patient has anemia, 
an investigation on the possible causes must be carried out 
to evaluate the presence of iron, B12 or folate deficiency, 
hemorrhage or hemolysis. In the absence of a cause that 
can explain the anemia or if it persists after the treatment 
of the underlying cause, erythropoietin-stimulating agents 
(ESAs) and blood transfusions must be considered. Re-
commendations regarding the use of ESAs were publi-
shed by the American Society of Oncology (ASCO) and 
the American Society of Hematology (ASH) in 2002 and 
updated in 200786.
The use of epoetin and darbepoetin for anemia treat-
ment associated with CT that is “close to or below 10 g/dL” 
is recommended to increase hemoglobin levels and decre-
ase the number of transfusions. It has been described that 
blood transfusions are a therapeutic option in several cli-
nical situations. Among the information mentioned by the 
recommendations is a meta-analysis, which showed that 
the highest evidence of benefit regarding quality of life and 
lowest need for blood transfusions is found in the group 
that received basal epoetin and hemoglobin ≤ 10 g/dL87. 
According to a systematic review, there was no statistically 
significant difference between the use of epoetin and dar-
bopoetin88. Iron deficiency diagnosis and treatment are 
recommended, when detected86.  
A concern regarding the use of ESAs lies in the increa-
sed risk of thromboembolic events when these medication 
are used, which is supported by a meta-analysis available 
at the Cochrane database of 200689. In spite of the lower 
quality of the studies included in this database, according 
to an Update Committee, caution is recommended when 
using ESAs in patients considered to be high-risk for the 
development of thromboembolic events, especially regar-
ding patients with multiple myeloma treated with thalido-
mide or lenalidomide86.
Additional concerns have arisen, as two clinical place-
bo-controlled phase II studies published in 2003, among 
others published after that, showed that there is evidence 
related to higher mortality and  less local regional pro-
gression-free time in patients treated with ESAs. More 
than 50% of the trials were carried out in patients that 
were not receiving CT, in most of which a hemoglobin 
level > 12 mg/dL was the objective and patients with he-
moglobin levels > 10 mg/dL before the clinical approach 
were not excluded. Although this information made the 
US Food and Drug Administration (FDA) add a restric-
tion warning to the prescription of epoetin and darbepoe-
tin in March 2007, the aforementioned Update Committee 
found it difficult to interpret and apply the recommenda-
tions to clinical practice. The NCCN recommendations 
say that the use of ESAs must be avoided in patients with 
anemia non-related to CT and that these drugs must be 
sued only in patients with hemoglobin levels < 10 mg/dL, 
aiming at a level that does not exceed 12 mg/dL73,86. The 
same group mentions that there is enough evidence to 
justify the use of ESAs in patients with anemia associated 
with a low risk of myelodiaplasia86.
GUARANA (PAULLINIA CUPANA)
Guarana (Paullinia cupana) is a plant native to the Ama-
zon basin, cultivated in Brazil and Venezuela, of which 
energetic and tonic properties have been known by the 
Maues natives, in Amazonas and also in Bahia. They used 
it before battles and during long walks to increase resis-
tance to thirst, heat and fatigue. It has been used as an “al-
ternative” medicine for several diseases such as headaches, 
indigestion, kidney dysfunction, muscle pain, menstrual 
cramps, depression and fatigue; it has been recently tested 
in a non-oncologic population and showed to be beneficial 
regarding the cognitive performance and mood improve-
ment, being well-tolerated at a dose of 75 mg90. 
The energetic and tonic properties of Guarana are due 
mainly to the methylxanthines present in its seeds, pre-
dominantly caffeine (trimethylxanthine). Caffeine, at the 
usually consumed doses, acts by blocking the action of en-
dogenous adenosine in its receptors, A1 and A2A. Adeno-
sine is a neurotransmitter or neuromodulator that causes 
sedation by inhibiting the release of several neurotrans-
mitters, such as norepinephrine, dopamine, acetylcholine, 
glutamate and GABA91. Caffeine, theobromine and theo-
phylline are called methylxanthines and are part of a group 
of compounds sometimes classified as true alkaloids (pu-
rine alkaloids), characterized by their anti-inflammatory 
activity.
In two studies carried out by our group, the dry extract 
of Guarana administered at a dose of 75 mg once a day, to 
patients undergoing RT and 50 mg twice a day, to patients 
undergoing CT for the treatment of breast cancer, showed 
a positive and significant result in the treatment of mental 
and physical fatigue in these patients. Therefore, Guarana 
has shown to be a promising option, with no side effects 
and affordable to our population92. 
OTHER PHARMACOLOGICAL AGENTS
Several other pharmacological treatments have been stu-
died for the treatment of CRF. The use of corticoids has 
resulted in a decrease in depression levels and analgesic 
consumption, as well as an increase in appetite and daily 
activities as shown in a small clinical, randomized place-
bo-controlled trial with 14 days of oral methylpredniso-
lone in patients with end-stage cancer93. However, larger 
studies involving the prolonged use of corticoids in other 
populations have not been carried out to date. Donepezil 
was studied in a randomized trial that did not show any 
CANCER-RELATED FATIGUE: A REVIEW
211Rev Assoc Med Bras 2011; 57(2):206-214
benefit when compared to placebo in patients that had 
CRF94. Studies have not yet demonstrated any significant 
benefit of using dextroamphetamine95, multivitamins96 or 
antidepressants97,98 in the treatment of fatigue. In a meta- 
analysis that evaluated the use of corticoids and paroxe-
tine, neither of the two substances showed a better result 
than the placebo group in the treatment of CRF82. 
COMBINED APPROACH IN THE TREATMENT OF CANCER 
RELATED FATIGUE 
Patients can benefit from a multimodal approach consis-
ting of several treatment strategies and the most promi-
nent example of this perspective carried out in practice is 
the Cancer-related Fatigue Clinic established in 1998 by 
M. D. Anderson Cancer Center. This clinic aims at impro-
ving patients’ quality of life through fatigue decrease. The 
project’s objective is to integrate the physical assessment of 
fatigue to the development of a treatment plan that inclu-
des pharmacological and non-pharmacological measures, 
as well as providing education aiming at family and caregi-
ver comprehension regarding the behavior of patients that 
have fatigue. Recently, the results of these interventions 
carried out between 1998 and 2005 have been published. 
Before the initial assessment, the patients were submit-
ted to laboratory evaluation that included electrolytes, 
red blood cells and thyroid hormones. The patients also 
answered a group of questionnaires that evaluated fatigue. 
At the initial consultation, the doctors defined and indi-
vidualized the treatment plan. The treatment modalities 
could include the treatment of reversible causes of fatigue 
or comorbidities; recommendations and discussions on 
fatigue, including the possibility of access to literature re-
lated to the theme, among other non-pharmacological and 
pharmacological measures offered as treatment modali-
ties. Fatigue was assessed using the BFI as severe (score of 
7-10) or non-severe (0-6), being subsequently subdivided 
in moderate (4-6) and mild (0-3). The primary objective 
was to reduce the fatigue score according to the implemen-
ted measures to reach such level of symptom improvement. 
The most commonly implemented measures were ECAM 
(98.5%), sleep hygiene (97%), physical exercises (95%), re-
laxation techniques (27%), use of antidepressants (27%), 
analgesics (25%), stimulants (22%), anxiolytics (17%) and 
nutritional counseling (10%)34.
Of more than 260 patients, 47% initially reported seve-
re fatigue, 42% reported moderate and 10% mild fatigue. 
Only 54% of the patients returned for a second scheduled 
consultation, and therefore, a loss of follow-up might have 
affected the results. Among the patients that were followed 
at a second visit, 59% achieved a decrease in fatigue of a 
least one category of the scores measured by the BFI. The 
generalization of results to other populations is uncertain, 
as many patients had requested a previous consultation at 
this clinic with the objective of treating their fatigue; most 
of the patients were Caucasians females, who were motiva-
ted to treat their symptoms. The most common malignant 
diseases found in these patients were breast cancer and he-
matological diseases34.
The algorithm shown in Figure 1 illustrates the appro-
ach used in patients with CRF. 
FINAL CONSIDERATIONS 
CRF is one of the most prevalent symptoms in cancer pa-
tients, being reported by 50% to 90% of all patients and 
severely affecting quality of life, in addition to decreasing 
the daily functional capacity of patients. Fatigue symptoms 
remain underreported and are not adequately treated. The 
current recommendations indicate the investigation of fa-
tigue at the patient’s initial consultation, when a diagnosis 
of advanced disease is achieved and at each visit for CT 
administration, as well as the identification of treatable 
causes and factors that contribute to the manifestation of 
this symptom. 
Standardized questionnaires must be used, such as the 
BFI and the VAS, as they are appropriate for the initial clas-
sification of fatigue. However, the initial approach of this 
symptom requires more than applying a questionnaire. A 
broad approach must be carried out with general recom-
mendations on fatigue, in addition to the establishment of 
an individualized therapeutic approach plan. Patients with 
moderate or severe fatigue can benefit from both phar-
macological and non-pharmacological measures, whereas 
those with mild fatigue that does not affect quality of life 
can be treated with non-pharmacological measures as the 
only therapeutic approach. 
The non-pharmacological treatment shows to be pro-
mising with measures such as cognitive-behavioral the-
rapies (ECAM), physical exercises and maybe sleep 
therapies. Other treatment modalities can be beneficial 
and used as individualized management; however, there 
scarce evidence to affirm that symptom improvement can 
be achieved with other therapy types.  
The pharmacological treatment has shown promising 
results that include the use of psycho-stimulants such as 
methylphenidate and dexmethylphenidate, modanafil (in 
patients with severe fatigue) and erythropoietin-stimula-
ting agents in patients with CT-related anemia and hemo-
globin < 10 mg/dL. Additionally, corticoids can be prescri-
bed to patients with terminal disease and severe fatigue. 
As there is no consensus regarding the cost-benefit 
of investing in clinical practice specialized only in CRF, a 
better treatment can be offered through a multimodal and 
multidisciplinary approach in a clinical practice that is at-
tentive to symptom improvement or worsening in these 
patients, with professionals that are aware of CRF patients’ 
symptoms. Each case must be individually evaluated and 
initially classified according to a scale of fatigue, anam-
nesis and physical examination, considering the patient’s 
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limitations and comorbidities and to what extent these 
symptoms are related to cancer and its treatment or if they 
were already present throughout the life of these patients 
due to other pathologies or activities developed by them. 
The fatigue will be present not only due to the disease, but 
also due to treatment given to the patient, which can cau-
se or aggravate the fatigue that had manifested previous-
ly. The limitations of each patient must be reassessed and 
discussed, so that the best treatment can be determined 
according to the patient’s perspective on the disease and 
the evolution of the pathology and its treatment. 
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